Wang et al. [39] demonstrated that image features (morphological, gray-level, and statistical texture measures) of breast tumors and their surrounding parenchyma on dynamic contrast enhancement (DCE)-MRI could distinguish triple-negative breast cancers from other subtypes with higher accuracy (AUC of 0.878) than when considering the characteristics of the tumor alone, because triple-negative breast cancer would have responses to neither hormonal therapy nor anti-HER2 therapy. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.